1-3 of 3
Umeer Ashraf, MD
Close
Sort by
Journal Articles

Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.

Umeer Ashraf, MD, Myron S. Czuczman, MD, Cory Marvis, MS, John Gibbs, MD, Francisco J Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2009) 114 (22): 3727.
https://doi.org/10.1182/blood.V114.22.3727.3727
Published: 2009
Journal Articles

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Umeer Ashraf, MD, Ritika Mahajan, MBBS, Theresa Hahn, PhD, Shannon L Smiley, MD, Philip L. McCarthy, MD, Zale P. Bernstein, MD, Asher Alban Chanan-Khan, MD, Minoo Battiwala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2008) 112 (11): 1138.
https://doi.org/10.1182/blood.V112.11.1138.1138
Published: 2008
Journal Articles

Emergence of Rituximab-Fludarabine Resistance Is Associated with Changes in CD20 Antigen Expression and Improved Response to Almetuzumab Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Umeer Ashraf, MD, Anjana N. Elefante, PharmD, Raymond Cruz, MD, Paul K. Wallace, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-llizaliturri, MD
Journal: Blood
Blood (2007) 110 (11): 2054.
https://doi.org/10.1182/blood.V110.11.2054.2054
Published: 2007